Mycobacterium ulcerans infection: Evolution in clinical management

ANZ Journal of Surgery

Volumn 83, Issue 7-8, 2013, Pages 523-526

  Simpson, Candice ^a   O'Brien, Daniel P ^a,b   Mcdonald, Anthony ^a   Callan, Peter ^a  

^a Barwon Health ^*  (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antibiotics; Bairsdale ulcer; Buruli ulcer; Debridement; Mycobacterium ulcerans

Indexed keywords

ANTIBIOTIC AGENT;

AUSTRALIA; BAIRSDALE ULCER; BURULI ULCER; DEBRIDEMENT; HUMAN; MYCOBACTERIUM ULCERANS; REVIEW;

ANTIBIOTICS; BAIRSDALE ULCER; BURULI ULCER; DEBRIDEMENT; MYCOBACTERIUM ULCERANS;

AUSTRALIA; BURULI ULCER; HUMANS;

EID: 84880988006     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2012.06230.x     Document Type: Review

References (25)

1. van der Werf TS, van der Graaf WTA, Tappero JW, Asiedu K. Mycobacterium ulcerans infection. Lancet 1999; 354: 1013-1018.
2. Johnson PDR, Stinear T, Small PLC etal. Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med. 2005; 2: e108.
3. Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, Grosset JH. Activities of rifampin, rifapentine and clarithromycin alone and in combination against Mycobacterium ulcerans disease in mice. PLoS Negl. Trop. Dis. 2011; 5: e933.
4. van der Werf TS, Stinear T, Stienstra Y, van der Graaf WTA, Small PL. Mycolactones and Mycobacterium ulcerans disease. Lancet 2003; 362: 1062-1064.
5. Chauty A, Ardant M-F, Adeye A etal. Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob. Agents Chemother. 2007; 51: 4029-4035.
6. Walsh DS, Portaels F, Meyers WM. Buruli ulcer: advances in understanding Mycobacterium ulcerans infection. Dermatol. Clin. 2011; 29: 1-8.
7. van der Werf TS, Stienstra Y, Johnson RC etal. Mycobacterium ulcerans disease. Bull. World Health Organ. 2005; 83: 785-791.
8. Sizaire V, Nackers F, Comte E, Portaels F. Mycobacterium ulcerans infection: control, diagnosis, and treatment. Lancet Infect. Dis. 2006; 6: 288-296.
9. Nienhuis WA, Stienstra Y, Thompson WA etal. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 2010; 375: 644-672.
10. Walsh DS, Portaels F, Meyers WM. Recent advances in leprosy and Buruli ulcer (Mycobacterium ulcerans infection). Curr. Opin. Infect. Dis. 2010; 23: 445-455.
11. Herbinger K-H, Brieske D, Nitschke J etal. Excision of pre-ulcerative forms of Buruli ulcer disease: a curative treatment? Infection 2009; 37: 20-25.
12. Wansbrough-Jones M, Phillips R. Buruli ulcer: emerging from obscurity. Lancet 2006; 367: 1846-1858.
13. Boyd S, Athan E, Friedman ND etal. Epidemiology, clinical features and diagnosis of Mycobacterium ulcerans in an Australian population. Med. J. Aust. 2012; 196: 341-344.
14. Asiedu K, Wansbrough-Jones M. Mycobacterium ulcerans infection (Buruli or BU): challenges in developing management strategies. Med. J. Aust. 2007; 186: 55-56.
15. Johnson PDR, Hayman JA, Quek TY etal. Consensus recommendations for the diagnosis, treatment and control of Mycobacterium ulcerans infection (Bairnsdale or Buruli ulcer) in Victoria, Australia. Med. J. Aust. 2007; 186: 64-68.
16. Jenkin GA, Smith M, Fairley M, Johnson PDR. Acute, oedematous Mycobacterium ulcerans infection in a farmer from far north Queensland. Med. J. Aust. 2002; 176: 182-183.
17. Steffen CM, Smith M, McBride WJH. Mycobacterium ulcerans infection in North Queensland: the 'Daintree ulcer'. ANZ J. Surg. 2010; 80: 732-736.
18. O'Brien DP, Hughes AJ, Cheng AC etal. Outcomes for Mycobaterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med. J. Aust. 2007; 186: 58-61.
19. Etuaful S, Carbonnelle B, Grosset J etal. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob. Agents Chemother. 2005; 49: 3182-3186.
20. Thangaraj HS, Adjei O, Allen BW etal. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. J. Antimicrob. Chemother. 2000; 45: 231-233.
21. Bentoucha A, Robert J, Dega H, Lounis N, Jarlier V, Grosset J. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 2001; 45: 3109-3112.
22. Sarfo FS, Phillips R, Asiedu K etal. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob. Agents Chemother. 2010; 54: 3678-3685.
23. Pak J, O'Brien DP, Queck T, Athan E. Treatment costs of Mycobacterium ulcerans in the antibiotic era. Int. Health 2012; 4: 123-127.
24. O'Brien DP, McDonald A, Callan P etal. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study. PLoS Negl. Trop. Dis. 2012; 6: e1473.
25. O'Brien DP, Robson ME, Callan PP, McDonald AH. 'Paradoxical' immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med. J. Aust. 2009; 191: 564-566.